Que Dallara introduces My Insights
In my first blog post, I referenced a first-of-its-kind program called My Insights made exclusively for individuals using our MiniMed™ 770G system. This month, I’m excited to share that we’ve launched My Insights in the U.S.
My Insights
My Insights is significant for two reasons:
- Actionable Insights: My Insights uses the power of data science to translate your diabetes data into tangible action you can take to help you reach your diabetes goals.
- Holistic Support: With the program, we’re leveraging a holistic approach to enhance your experience on our insulin pump systems starting with our MiniMed™ 770G system and expanding to our next-generation platforms. We want you to have the best possible experience on our technology and the data gleaned from CareLink™ will help us do just that.
This program goes beyond generalized tips and elevates your diabetes experience by delivering personalized and actionable insights for your individual diabetes management. Monthly emails include:
 Your latest Time in Range trends |
 Personalized opportunities from your data |
 Unique support resources |
 Motivation & achievement badges |
As with any technology, everyone has a unique experience so it’s important for us to leverage data science to provide a more tailored report that resonates with your specific needs.
What Matters Most
Ultimately, what’s most important to us is your experience. We were intentional about launching a pilot to ensure we got feedback from customers so we could deliver the most meaningful program to you. I am very pleased and excited to see that the reports resonate with so many of you including Melanie, a 22-year Medtronic pumper who recently enrolled in My Insights.
"I did not expect the emotion I got from the encouragement. I didn’t realize that was something I was missing and really appreciated.”― Melanie
Melanie has a young teenage son who plays hockey, and she enjoys traveling with him for his games. Prior to using the MiniMed 770G system, she was hesitant to travel alone with her son. Melanie was concerned about the potential negative experience that might create for her son. Since she started receiving My Insights customized reports available with her pump, Melanie has made adjustments that provide her with more comfort and confidence to travel with her son. One small change recommended for Melanie was to calibrate before bed to avoid the frequent waking she was experiencing ― Melanie raved about this tip. Changes like this allow Melanie to enjoy all the moments that matter most to her.
Your Insights
If you use the MiniMed 770G insulin pump and sensor, you can start receiving My Insights emails by updating your communication preferences in Diabetes.shop. Once you opt-in to “Personalized Insights,” you’ll receive a report with customized and individualized recommendations within a few weeks. As someone who is passionate about software and data, I love seeing how our current loop system can be combined with data science to evolve diabetes management.
Whether it be by proactively addressing challenges or celebrating successes, our goal is to encourage and empower individuals who use our latest technology, and My Insights is one way we’re able to do just that.
I’d love to hear from you about your My Insights experience. Share your comments below!
Warmly,
Que
Let’s stay in touch! Update your communication preferences by visiting your profile in Diabetes.shop. Simply login or register your account to ensure you receive communications when and how you want to receive them.
How to set your email preferences
Important Safety Information: MiniMed™ 770G System With SmartGuard™ Technology
The MiniMed™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 770G System includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose values (SG) and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed™ 770G System consists of the following devices: MiniMed™ 770G Insulin Pump, the Guardian™ Link (3) Transmitter, the Guardian™ Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the AccuChek®Guide Test Strips. The system requires a prescription.
The Guardian™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ Sensor (3).
All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.
WARNING: Do not use the SmartGuard™ Auto Mode for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in SmartGuard™ Auto Mode. |
WARNING: Do not use the MiniMed™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 770G system.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safetyinformation#minimed-7… and the appropriate user guide at https://www.medtronicdiabetes.com/download-library
Related Articles
About Author
Que Dallara
EVP and PresidentQue Dallara joined Medtronic as EVP and President of the Diabetes business in May of 2022. Before joining Medtronic, Que served as President and CEO of Honeywell Connected Enterprise, Honeywell’s software business. Prior to that, she was SVP and chief commercial officer leading Honeywell's efforts in brand, strategy, marketing, sales excellence, pricing, product innovation, including enterprise software, data analytics and IOT solutions.